New non-opioid treatment options are important given the national crisis related to opioid abuse."īack problems are one of the top 10 most expensive medical conditions, with an estimated 30 percent of the 300,000 patients annually that undergo lumbosacral spine procedures developing chronic intractable pain. "This platform represents a welcome new option for managing some kinds of chronic pain. Lance Roy, pain medicine specialist at Duke University Medical Center.
![medtronic dorsal column stimulators medtronic dorsal column stimulators](https://www.healthplexus.net/files/content/2017/0708/0708pain_m2.png)
Having real-time data can provide more information about patients' quality of life changes," said Dr. implanted one of the first patients in the U.S. The Intellis platform can record and track patient activity 24/7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients' therapy needs.ĭuke University Medical Center in Durham, N.C. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the EvolveSM workflow, which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings. launch of the Intellis platform for the management of certain types of chronic intractable pain. Medtronic plc announced FDA approval and U.S.